- Charity Medecins Sans Frontieres has accused U.S. drugmaker Gilead
Sciences Inc GILD.O of restricting access to its breakthrough hepatitis C
drug Sovaldi in developing countries as it tries to protect profit
margin in wealthier nations.
also known as Doctors Without Borders, said Gilead's restrictions aimed
to stop discounted supplies of Sovaldi being diverted to patients from
rich countries, but that the effort had resulted in "multiple
restrictions and demands" on people receiving treatment in poor
said Gilead was excluding people without national identity documents, a
move that hurts migrants, refugees and marginalized patients.
Labels: activism, Doctors without Borders, Gilead, global access, Medecins Sans Frontieres (MSF), Sovaldi